ArticleJournal of clinical medicine2024
The Role of Pan-Immune-Inflammation Value in Determining the Severity of Coronary Artery Disease in NSTEMI Patients.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Prognostic Value of Dynamic Hematologic Immune-Inflammatory Indices in Patients Undergoing Isolated Coronary Artery Bypass Grafting.Journal of clinical medicine · 2026Article
- Article
- Association of routine inflammatory biomarkers and derived indices with heart failure progression in preserved ejection fraction.BMC cardiovascular disorders · 2026Article
- Clinical Association of Pan-Immune-Inflammation Value with MEFV Mutation Burden and Amyloidosis in Adults with Familial Mediterranean Fever: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Prognostic Value of the Cumulative Inflammatory Index (IIC) in Patients with Non-ST-Segment Elevation Myocardial Infarction.Biomedicines · 2026Article
- Pan-Immune-Inflammation Value as a Novel Predictor of Contrast-Associated Acute Kidney Injury in Patients Treated with Primary PCI for STEMI.Journal of clinical medicine · 2026Article
- Pan-Immune-Inflammatory Value (PIV) and HALP Score as Independent Prognostic Indicators in Acute Coronary Syndrome Patients.Journal of clinical medicine · 2026Article
- Endothelial progenitor cells and circulating microRNAs as possible biomarkers for coronary artery disease.Frontiers in aging · 2026Article
- Clinical utility of CBC-Derived inflammatory markers for predicting IVIG resistance: findings from a Korean infant Kawasaki disease cohort.Pediatric rheumatology online journal · 2025Article
- A New Perspective on NSTE-ACS Patients in the Emergency Department: Cardiac Risk Prediction with New Inflammation Markers.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort.International journal of molecular sciences · 2025Article
- Inflammatory Markers and Saphenous Vein Graft Stenosis: Insights into the Use of Glucose-to-Lymphocyte Ratio as a Prognostic Marker.Journal of clinical medicine · 2025Article
- Prognostic Role of Pan-Immune-Inflammatory Value in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.Journal of cardiovascular development and disease · 2025Article
- Automatic Detection of Occluded Main Coronary Arteries of NSTEMI Patients with MI-MS ConvMixer + WSSE Without CAG.Diagnostics (Basel, Switzerland) · 2025Article
- Predictive value of dynamic changes in RvD1, sST2, and PIV levels for the prognosis of STEMI patients after PCI: a prospective study.Frontiers in cardiovascular medicine · 2025Article
- Investigation of the relationship between the triglyceride-glucose index and metabolic and hematological parameters in obese individuals.Turkish journal of medical sciences · 2025Article
- Valvular dysfunction and cardiovascular risk in individuals with opioid use disorder who are maintained on buprenorphine/naloxone: a focus on pan-immune-inflammation value and uric acid-to-albumin ratio.Frontiers in cardiovascular medicine · 2025Article
- Pan-Immune-Inflammatory Value Predicts the Risk of Myocardial Infarction Among Patients with Unstable Angina Pectoris and the Outcomes After Percutaneous Coronary Intervention.International journal of general medicine · 2025Article
- Association Between Pan-Immune-Inflammation Value and Dipper/Non-Dipper Status in Newly Diagnosed Hypertensive Patients.Journal of inflammation research · 2025Article
- Looking Back, Leaning Forward-A Contemporary Overview of Acute Coronary Syndrome.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEven though medication and interventional therapy have improved the death rate for non-ST elevation myocardial infarction (NSTEMI) patients, these patients still have a substantial residual risk of cardiovascular events. Early identification of high-risk individuals is critical for improving prognosis, especially in this patient group. The focus of recent research has switched to finding new related indicators that can help distinguish high-risk patients. For this purpose, we examined the relationship between the pan-immune-inflammation value (PIV) and the severity of coronary artery disease (CAD) defined by the SYNTAX score (SxS) in NSTEMI patients.
methodsBased on the SxS, CAD patients were split into three groups. To evaluate the risk variables of CAD, multivariate logistic analysis was employed.
resultsThe PIV (odds ratio: 1.003; 95% CI: 1.001-1.005;
conclusionsIn patients with non-STEMI, the PIV, a cheap and easily measured laboratory variable, was substantially correlated with a high SxS and the severity of CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.